RHHBY Stock Recent News

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today plans to invest more than $700 million in a new 700,000 square foot state-of-the-art drug manufacturing facility in Holly Springs, NC. The project will add more than 400 high-wage manufacturing jobs when the site is operational and more than 1,500 construction jobs during site development. The new facility will ultimately support Roche and Genentech's future portfol.

Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.

Basel, 06 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of its Elecsys® PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients showing signs of metabolic dysfunction–associated steatotic liver disease (MASLD). The test, developed in partnership with Nordic Bioscience, offers clinicians a simple and efficient method of identifying patients with liver fibrosis of varying severity, enabling timely intervention and appropriate management of the disease.

Jack Roche, The Hanover Group CEO, joins 'The Exchange' to discuss the company's quarterly earnings results, how tariffs are impacting Roche's business, what's next for insurance premiums, and much more.

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives at both firms told CNBC a "very competitive process" left both firms hashing out the details until the eleventh hour.

Does Roche Holding AG (RHHBY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here is how Roche Holding AG (RHHBY) and argenex SE (ARGX) have performed compared to their sector so far this year.

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Blood-Based Biomarker Market - A Global and Regional Analysis: Focus on Disease, Application, and Country-Level Analysis, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global blood-based biomarker market is poised for substantial growth, driven by the increasing demand for non-invasive diagnostic techniques and advancements in biomarker discovery for diseases such as cancer, neurological disorders, and various others.

Basel, 30 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an update to the European Union (EU) label for Phesgo®, a subcutaneous (SC) fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. If approved, administration of Phesgo outside of a clinical setting (such as in a person's home) by a healthcare professional will be possible, once safely established in a clinical setting. A final decision regarding the approval is expected from the European Commission in the near future.

David Roche of Quantum Strategy says a weaker dollar will drive 10-year yields to 5.5%, which will threaten the dollar's dominance. He says the Fed can do little to prevent this selling of treasuries.